• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson beats The Street in Q3, MedTech sales rise

Johnson & Johnson beats The Street in Q3, MedTech sales rise

October 18, 2022 By Sean Whooley

johnson & johnson or J&J logoJohnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with MedTech business sales up more than 2%.

The New Brunswick, New Jersey-based company posted profits of $4.5 billion, or $1.68 per share in the quarter. It pulled in sales of $23.8 billion for the three months ended Sept. 30, 2022. That marked a 21.6% bottom-line gain on sales growth of 1.9%.

Adjusted to exclude one-time items, earnings per share were $2.48. That beat Wall Street expectations by 7¢, while analysts looked for sales of $23.3 billion.

J&J’s MedTech arm also saw rises during the quarter. It posted sales of nearly $6.8 billion for a 2.1% improvement over this time last year. The company attributed the performance to drivers such as electrophysiology products, contact lenses, orthopedic trauma therapies and wound closure products.

Its Pharmaceutical business performed the best with revenues of $13.2 million (up 2.6% on 2021).

“Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Johnson & Johnson CEO. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions.

“Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”

Johnson & Johnson projects sales between $93 billion and $93.5 billion in 2022. That marks a slight dip from July’s guidance for between $93.3 billion and $94.3 billion.

The company also raised the low end of its adjusted EPS guidance but reeled in the high end. It now projects for between $10.02 and $10.07. The company previously expected a range between $10 and $10.10.

More about J&J MedTech’s performance

Truist analysts noted that Johnson & Johnson’s MedTech business saw strong volume recovery late in Q3. The sales strength was most pronounced for interventional solutions/interventional cardio (i.e. cath lab procedures). Orthopedics also saw recovery, but not as much as the company saw with cath lab procedures.

Richard Newitter, David Rescott, Samuel Brodovsky, and Lin Zhang at Truist noted that J&J management still view M&A deals as a key priority for MedTech. In fact, they appear bullish on such deals. But they also added that executives commentary “suggested that volatility in capital markets has created some hesitancy in target companies willingness to sell at these sedated valuations.”

JNJ shares were up slightly at $166.93 apiece in morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up nearly 5%.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, News Well, Wall Street Beat Tagged With: Johnson & Johnson, Johnson & Johnson MedTech

More recent news

  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy